Guardant Health, Inc. (NASDAQ:GH) Position Increased by SWS Partners

SWS Partners lifted its position in Guardant Health, Inc. (NASDAQ:GH) by 44.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 120,888 shares of the company’s stock after buying an additional 37,126 shares during the quarter. Guardant Health makes up about 1.1% of SWS Partners’ holdings, making the stock its 20th largest holding. SWS Partners’ holdings in Guardant Health were worth $3,693,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in GH. JNBA Financial Advisors purchased a new position in shares of Guardant Health during the third quarter valued at $26,000. R Squared Ltd acquired a new stake in Guardant Health during the 4th quarter worth about $26,000. Ashton Thomas Securities LLC purchased a new position in Guardant Health during the 3rd quarter valued at about $34,000. SBI Securities Co. Ltd. acquired a new position in shares of Guardant Health in the 4th quarter valued at about $43,000. Finally, Nisa Investment Advisors LLC lifted its position in shares of Guardant Health by 168.1% in the third quarter. Nisa Investment Advisors LLC now owns 3,434 shares of the company’s stock worth $79,000 after purchasing an additional 2,153 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on GH shares. Scotiabank boosted their price objective on shares of Guardant Health from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Monday, February 24th. JPMorgan Chase & Co. boosted their price target on shares of Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, February 21st. The Goldman Sachs Group upped their price target on shares of Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Raymond James reissued an “outperform” rating and set a $59.00 price objective (up previously from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Finally, Canaccord Genuity Group boosted their target price on Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a research note on Monday, February 24th. Nineteen equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $48.21.

Guardant Health Trading Down 4.3 %

Shares of Guardant Health stock opened at $40.74 on Tuesday. The firm has a fifty day simple moving average of $41.09 and a 200-day simple moving average of $32.01. The stock has a market capitalization of $5.03 billion, a price-to-earnings ratio of -11.44 and a beta of 1.32. Guardant Health, Inc. has a 1-year low of $15.81 and a 1-year high of $50.89.

Guardant Health (NASDAQ:GH) last announced its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. As a group, research analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Musa Tariq sold 2,320 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the completion of the transaction, the director now directly owns 2,676 shares in the company, valued at $93,660. This represents a 46.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders sold 2,668 shares of company stock valued at $95,208. Insiders own 5.50% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.